Cited by 1,093Diabetes and associated disordersT-cell and B-cell ImmunologyDiabetes Management and Research

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

Open access

Pescovitz, Mark D., Greenbaum, Carla J., Krause-Steinrauf, Heidi, Becker, Dorothy J., Gitelman, Stephen E., Goland, Robin, Gottlieb, Peter A., Marks, Jennifer B., McGee, Paula F., Moran, Antoinette M., Raskin, Philip, Rodriguez, Henry, Schatz, Desmond A., Wherrett, Diane, Wilson, Darrell M., Lachin, John M., Skyler, Jay S.·2009·New England Journal of Medicine

DOI 10.1056/nejmoa0904452PMC PMC6410357

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The immunopathogenesis of type 1 diabetes mellitus is associated with T-lymphocyte autoimmunity. However, there is growing evidence that B lymphocytes play a role in many T-lymphocyte-mediated diseases. It is possible to achieve selective depletion of B lymphocytes with rituximab, an anti-CD20 monoclonal antibody. This phase 2 study evaluated the role of B-lymphocyte depletion in patients with type 1 diabetes. METHODS: We conducted a randomized, double-blind study in which 87 patients between 8 and 40 years of age who had newly diagnosed type 1 diabetes were assigned to receive infusions of rituximab or placebo on days 1, 8, 15, and 22 of the study. The primary outcome, assessed 1 year after the first infusion, was the geometric mean area under the curve (AUC) for the serum C-peptide level during the first 2 hours of a mixed-meal tolerance test. Secondary outcomes included safety and changes in the glycated hemoglobin level and insulin dose. RESULTS: At 1 year, the mean AUC for the level of C peptide was significantly higher in the rituximab group than in the placebo group. The rituximab group also had significantly lower levels of glycated hemoglobin and required less insulin. Between 3 months and 12 months, the rate of decline in C-peptide levels in the rituximab group was significantly less than that in the placebo group. CD19+ B lymphocytes were depleted in patients in the rituximab group, but levels increased to 69% of baseline values at 12 months. More patients in the rituximab group than in the placebo group had adverse events, mostly grade 1 or grade 2, after the first infusion. The reactions appeared to be minimal with subsequent infusions. There was no increase in infections or neutropenia with rituximab. CONCLUSIONS: A four-dose course of rituximab partially preserved beta-cell function over a period of 1 year in patients with type 1 diabetes. The finding that B lymphocytes contribute to the pathogenesis of type 1 diabetes may open a new pathway for exploration in the treatment of patients with this condition. (ClinicalTrials.gov number, NCT00279305.)

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa0904452

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,996
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E., Harlan, D. M., Xu, D., Zivin, R. A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012864 · Cited by 1,222
Self-citation
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes
Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043980 · Cited by 1,099
Autoimmune Diseases
Davidson, A., & Diamond, B. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108023450506 · Cited by 1,069
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trial
Emery, P., Fleischmann, R., Filipowicz‐Sosnowska, A., Schechtman, J., Szczepanski, L., Kavanaugh, A., Racewicz, A. J., van Vollenhoven, R., Li, N. F., Agarwal, S. K., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21778 · Cited by 1,061
The Autoimmune Diseases
(2006) · Elsevier eBooks · doi:10.1016/b978-0-12-595961-2.x5000-8 · Cited by 963
B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximab
Looney, R. J., Anolik, J. H., Campbell, D., Felgar, R. E., Young, F. M., Arend, L. J., Sloand, J. A., Rosenblatt, J. D., & Sanz, I. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20430 · Cited by 779
Rituximab, an Anti-CD20 Monoclonal Antibody: History and Mechanism of Action
Pescovitz, M. D. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01288.x · Cited by 626
Self-citation

Flagged first, then by citations

Show all 39 references

Research works printed but not linked: 1

Lapointe R, 2003, Cancer Res, 63, 2836

Sorted by citations

Items 501–600 of 1,000

Nanotargeted Delivery of Immune Therapeutics in Type 1 Diabetes
Jung, S., Nasr, M. B., Bahmani, B., Usuelli, V., Zhao, J., Sabiu, G., Seelam, A. J., Naini, S. M., Balasubramanian, H. B., Park, Y., et al. (2023) · Advanced Materials · doi:10.1002/adma.202300812 · Cited by 18
PD-1 Receptor (+) T cells are associated with the efficacy of the combined treatment with regulatory t cells and rituximab in type 1 diabetes children via regulatory t cells suppressive activity amelioration
Zieliński, M., Sakowska, J., Iwaszkiewicz‐Grześ, D., Gliwiński, M., Hennig, M., Żalińska, M., Wołoszyn‐Durkiewicz, A., Jaźwińska-Curyłło, A., Kamińska, H., Owczuk, R., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111919 · Cited by 19
Successes and Disappointments with Clinical Islet Transplantation
Cravedi, P., van der Meer, I. M., Cattaneo, S. G. D. A., Ruggenenti, P. L., & Remuzzi, G. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-90-481-3271-3_33 · Cited by 17
In Vivo Islet Protection by a Nuclear Import Inhibitor in a Mouse Model of Type 1 Diabetes
Moore, D. J., Zienkiewicz, J., Kendall, P. L., Liu, D., Liu, X., Veach, R. A., Collins, R. D., & Hawiger, J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013235 · Cited by 17
Association of BANK1 and cytokine gene polymorphisms with type 1 diabetes in Tunisia
Zouidi, F., Stayoussef, M., Bouzid, D., Fourati, H., Abida, O., Costa, J., Ayed, M. B., Fakhfakh, R., Kammoun, T., Hachicha, M., et al. (2013) · Gene · doi:10.1016/j.gene.2013.12.008 · Cited by 17
Long-Term Safety of α-1 Antitrypsin Therapy in Children and Adolescents with Type 1 Diabetes
Brener, A., Lebenthal, Y., Interator, H., Horesh, O., Leshem, A., Weintrob, N., Loewenthal, N., Shalitin, S., & Rachmiel, M. (2018) · Immunotherapy · doi:10.2217/imt-2018-0047 · Cited by 17
Prevention of Type 1 Diabetes: Past Experiences and Future Opportunities
Beik, P., Ciesielska, M., Kucza, M., Kurczewska, A., Kuźmińska, J., Maćkowiak, B., & Niechciał, E. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092805 · Cited by 18
TLR9 Deficiency in B Cells Promotes Immune Tolerance via Interleukin-10 in a Type 1 Diabetes Mouse Model
Sha, S., Pearson, J. A., Peng, J., Hu, Y., Huang, J., Xing, Y., Zhang, L., Zhu, Y., Zhao, H., Wong, F. S., et al. (2020) · Diabetes · doi:10.2337/db20-0373 · Cited by 17
A century later, still fighting back: antigen‐specific immunotherapies for type 1 diabetes
Rodríguez-Fernández, S., Almenara‐Fuentes, L., Perna‐Barrull, D., Barneda‐Zahonero, B., & Vives‐Pi, M. (2021) · Immunology and Cell Biology · doi:10.1111/imcb.12439 · Cited by 17
Trials in the Prevention of Type 1 Diabetes: Current and Future
Wherrett, D. K. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2014.05.004 · Cited by 17
Self-citation
RNase L contributes to experimentally induced type 1 diabetes onset in mice
Zeng, C., Yi, X., Zipris, D., Liu, H., Zhang, L., Zheng, Q., Malathi, K., Jin, G., & Zhou, A. (2014) · Journal of Endocrinology · doi:10.1530/joe-14-0509 · Cited by 17
Follicular Regulatory T Cells Are Associated With β-Cell Autoimmunity and the Development of Type 1 Diabetes
Xu, X., Shen, M., Zhao, R., Cai, Y., Jiang, H., Shen, Z., Gao, R., Xu, K., Chen, H., & Yang, T. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00093 · Cited by 17
Persistence is the Twin Sister of Excellence
Greenbaum, C., & Atkinson, M. A. (2011) · Diabetes · doi:10.2337/db10-1810 · Cited by 17
Self-citation
Mechanism and therapeutic targets of circulating immune cells in diabetic retinopathy
Zhao, B., Zhao, Y., & Sun, X. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107505 · Cited by 19
B-cell exposure to self-antigen induces IL-10 producing B cells as well as IL-6- and TNF-α-producing B-cell subsets in healthy humans
Langkjær, A., Kristensen, B., Hansen, B. E., Schultz, H. S., Hegedűs, L. D., & Nielsen, C. H. (2012) · Clinical Immunology · doi:10.1016/j.clim.2012.07.004 · Cited by 16
Otelixizumab in the Treatment of Type 1 Diabetes Mellitus
Sprangers, B., der Schueren, B. V., Gillard, P., & Mathieu, C. (2011) · Immunotherapy · doi:10.2217/imt.11.123 · Cited by 16
Evaluation of dry blood spot technique for quantification of an Anti-CD20 monoclonal antibody drug in human blood samples
Lin, Y.-Q., Zhang, Y., Li, C., Li, L., Zhang, K., & Li, S. (2011) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2011.11.003 · Cited by 16
Therapie des Typ-1-Diabetes
Böhm, B., Dreyer, M., Fritsche, A., Füchtenbusch, M., Gölz, S., & Martin, S. (2012) · Diabetologie und Stoffwechsel · doi:10.1055/s-0032-1325579 · Cited by 16
Regulation of Diabetogenic Immunity by IL-15–Activated Regulatory CD8 T Cells in Type 1 Diabetes
Stocks, B. T., Wilson, C., Marshall, A. F., Hoopes, E. M., & Moore, D. J. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800976 · Cited by 17
Phenotypically distinct anti-insulin B cells repopulate pancreatic islets after anti-CD20 treatment in NOD mice
Boldison, J., da Rosa, L. C., Buckingham, L., Davies, J. E., Li, W., & Wong, F. S. (2019) · Diabetologia · doi:10.1007/s00125-019-04974-y · Cited by 16
Factors Associated With the Decline of C-Peptide in a Cohort of Young Children Diagnosed With Type 1 Diabetes
Steck, A. K., Liu, X., Krischer, J. P., Haller, M. J., Veijola, R., Lundgren, M., Ahmed, S. T., Akolkar, B., Toppari, J., Hagopian, W., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa715 · Cited by 17
Modeling Type 1 Diabetes Using Pluripotent Stem Cell Technology
Joshi, K., Cameron, F. J., Tiwari, S., Mannering, S. I., Elefanty, A. G., & Stanley, E. G. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.635662 · Cited by 18
Insulitis in Human Type 1 Diabetic Pancreas: From Stem Cell Grafting to Islet Organoids for a Successful Cell-Based Therapy
Noce, M. L., Nicoletti, G. F., Papaccio, G., Vecchio, V. D., & Papaccio, F. (2022) · Cells · doi:10.3390/cells11233941 · Cited by 15
Biotherapies targeting T and B cells: from immune suppression to immune tolerance
Chatenoud, L. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.05.013 · Cited by 16
Low‐dose anti‐ CD 3 antibody induces remission of active autoimmune hepatitis in xenoimmunized mice
Marceau, G., Yang, R., Lapierre, P., Béland, K., & Álvarez, F. (2014) · Liver International · doi:10.1111/liv.12498 · Cited by 17
HLA-DR4–Associated T and B Cell Responses to Specific Determinants on the IA-2 Autoantigen in Type 1 Diabetes
McLaughlin, K. A., Gulati, K., Richardson, C. C., Morgan, D., Bodansky, H. J., Feltbower, R. G., & Christie, M. R. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301902 · Cited by 16
Targeting Anti-Insulin B Cell Receptors Improves Receptor Editing in Type 1 Diabetes–Prone Mice
Bonami, R. H., & Thomas, J. W. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500438 · Cited by 16
DiaPep277® and immune intervention for treatment of type 1 diabetes
Schloot, N. C., & Cohen, I. R. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.09.001 · Cited by 16
Nanomedicine targeting the PD-1/PD-L1 axis in autoimmune diseases: breaking conventional barriers to restore immune tolerance
Xiang, G., Cui, Y., Wang, P., Feng, Y., Zhang, C., Lou, J., & Zhou, X. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03766-4 · Cited by 19
DiaPep277 peptide therapy in the context of other immune intervention trials in type 1 diabetes
Tuccinardi, D., Fioriti, E., Manfrini, S., D'Amico, E., & Pozzilli, P. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.599319 · Cited by 15
A nondepleting anti-CD19 antibody impairs B cell function and inhibits autoimmune diseases
Boyles, J. S., Sadowski, D. H., Potter, S. C., Vukojicic, A., Parker, J. T., Chang, W. Y., Ma, Y. L., Chambers, M. G., Nelson, J., Barmettler, B., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.166137 · Cited by 15
Historical Insights and Current Perspectives on the Diagnosis and Management of Presymptomatic Type 1 Diabetes
Simmons, K. M., Frohnert, B. I., O’Donnell, H. K., BAUTISTA, K. A., Rasmussen, C. G., Gonzalez, A. G., Steck, A. K., & Rewers, M. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0276 · Cited by 16
Innate and adaptive immune gene expression profiles as biomarkers in human type 1 diabetes
Han, D., Cai, X., Wen, J., Matheson, D., Skyler, J. S., Kenyon, N. S., & CHEN, Z. (2012) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2012.04650.x · Cited by 15
Self-citation
Targeting the trimolecular complex
Michels, A. W. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.02.020 · Cited by 16
Prevention versus intervention of type 1 diabetes
Brooks‐Worrell, B., & Palmer, J. P. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.05.018 · Cited by 15
B cell depletion in treating primary biliary cirrhosis: Pros and cons
Yin, Y. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i30.3938 · Cited by 15
CD83 Antibody Inhibits Human B Cell Responses to Antigen as well as Dendritic Cell–Mediated CD4 T Cell Responses
Wong, K. Y., Baron, R., Seldon, T. A., Jones, M. L., Rice, A. M., & Munster, D. J. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1700064 · Cited by 15
Combined Vitamin D, Ibuprofen and Glutamic Acid decarboxylase-alum Treatment in Recent Onset Type I Diabetes: Lessons from the DIABGAD Randomized Pilot Trial
Ludvigsson, J., Routray, I., Elluru, S. R., Leanderson, P., Larsson, H. E., Rathsman, B., Hanås, R., Carlsson, A., Ek, T., Samuelsson, U., et al. (2020) · Future Science OA · doi:10.2144/fsoa-2020-0078 · Cited by 14
Current and emerging therapies for Addison's disease
Napier, C., & Pearce, S. H. S. (2014) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000067 · Cited by 15
Type 1 diabetes: what is the role of autoimmunity in β cell death?
Donath, M. Y. (2022) · Journal of Clinical Investigation · doi:10.1172/jci164460 · Cited by 15
Biomarkers of autoimmunity and beta cell metabolism in type 1 diabetes
Yang, M., Kibbey, R. G., & Mamula, M. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1028130 · Cited by 16
GAD-Alum Immunotherapy in Type 1 Diabetes Mellitus
Morales, A. E., & Thrailkill, K. M. (2011) · Immunotherapy · doi:10.2217/imt.11.9 · Cited by 15
Disease modifying therapies in type 1 diabetes: Where have we been, and where are we going?
Lord, S. M., & Greenbaum, C. J. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.02.002 · Cited by 15
Self-citation
To B or not to B — pathogenic and regulatory B cells in autoimmune diabetes
Wong, F. S., Hu, C., Xiang, Y., & Li, W. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.10.002 · Cited by 15
Experiments by nature: lessons on type 1 diabetes
Battaglia, M. (2013) · Tissue Antigens · doi:10.1111/tan.12280 · Cited by 14
Germinal centre frequency is decreased in pancreatic lymph nodes from individuals with recent-onset type 1 diabetes
O’Connell, A., Richardson, S. J., Walker, L. S. K., Kent, S. C., Morgan, N. G., & Gillespie, K. M. (2017) · Diabetologia · doi:10.1007/s00125-017-4221-7 · Cited by 16
Dextran Sulfate Protects Pancreatic β-Cells, Reduces Autoimmunity, and Ameliorates Type 1 Diabetes
Lu, G., Rausell-Palamos, F., Zhang, J., Zheng, Z., Zhang, T., Valle, S. R., Rosselot, C., Berrouet, C. C., Conde, P., Spindler, M. P., et al. (2020) · Diabetes · doi:10.2337/db19-0725 · Cited by 15
Tetrahedral Framework Nucleic Acids Reverse New-Onset Type 1 Diabetes
Gao, S., Zhou, M., Li, Y., Xiao, D., Wang, Y., Yao, Y., Gao, Y., Cai, X., & Lin, Y. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c16151 · Cited by 14
Integrated Analysis of Single-Cell RNA-Seq and Bulk RNA-Seq Combined with Multiple Machine Learning Identified a Novel Immune Signature in Diabetic Nephropathy
Peng, Y.-L., Zhang, Y., Pang, L., Dong, Y.-F., Li, M.-Y., Liao, H., & Li, R. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s413569 · Cited by 14
Complement Cascade Proteins Correlate with Fibrosis and Inflammation in Early-Stage Type 1 Diabetic Kidney Disease in the Ins2Akita Mouse Model
Tserga, A., Saulnier‐Blache, J. S., Palamaris, K., Pouloudi, D., Gakiopoulou, H., Zoidakis, J., Schanstra, J. P., Vlahou, A., & Makridakis, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031387 · Cited by 14
Shifting the paradigm of type 1 diabetes: a narrative review of disease-modifying therapies
O’Donovan, A. J., Gorelik, S., & Nally, L. M. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1477101 · Cited by 14
Pre-Type 1 Diabetes in Adolescents and Teens: Screening, Nutritional Interventions, Beta-Cell Preservation, and Psychosocial Impacts
Sundheim, B., Hirani, K., Blaschke, M., Lemos, J. R. N., & Mittal, R. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020383 · Cited by 15
Regulatory T cell phenotype and function 4 years after GAD–alum treatment in children with type 1 diabetes
Pihl, M., Åkerman, L., Axelsson, S., Chéramy, M., Hjorth, M., Mallone, R., Ludvigsson, J., & Casas, R. (2013) · Clinical & Experimental Immunology · doi:10.1111/cei.12078 · Cited by 14
Mechanisms of autoimmunity in human diseases: a critical review of current dogma
Benson, R., Brewer, J., & Platt, A. M. (2014) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000037 · Cited by 17
B cell immunotherapy in autoimmunity – 2010 update
Chan, A. C. (2010) · Molecular Immunology · doi:10.1016/j.molimm.2010.11.021 · Cited by 14
Healthy Donor Polyclonal IgMs Diminish B-Lymphocyte Autoreactivity, Enhance Regulatory T-Cell Generation, and Reverse Type 1 Diabetes in NOD Mice
Wilson, C., Chhabra, P., Marshall, A. F., Morr, C. V., Stocks, B. T., Hoopes, E. M., Bonami, R. H., Poffenberger, G., Brayman, K. L., & Moore, D. J. (2018) · Diabetes · doi:10.2337/db18-0456 · Cited by 15
Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes
Lord, S. M., & Greenbaum, C. J. (2020) · F1000Research · doi:10.12688/f1000research.21801.1 · Cited by 15
Self-citation
B Quiet: Autoantigen-Specific Strategies to Silence Raucous B Lymphocytes and Halt Cross-Talk with T Cells in Type 1 Diabetes
Felton, J. L., Conway, H., & Bonami, R. H. (2021) · Biomedicines · doi:10.3390/biomedicines9010042 · Cited by 13
Polygenic autoimmune disease risk alleles impacting B cell tolerance act in concert across shared molecular networks in mouse and in humans
Harley, I. T. W., Allison, K., & Scofield, R. H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.953439 · Cited by 15
Changes in beta cell function during the proximate post-diagnosis period in persons with type 1 diabetes
DiMeglio, L. A., Cheng, P., Beck, R. W., Kollman, C., Ruedy, K. J., Slover, R. H., Aye, T., WEINZIMER, S. A., Bremer, A. A., & Buckingham, B. A. (2015) · Pediatric Diabetes · doi:10.1111/pedi.12271 · Cited by 14
Disease progression among 446 children with newly diagnosed type 1 diabetes located in Scandinavia, Europe, and North America during the last 27 yr
Andersen, M. L. M., Nielsen, L. B., Svensson, J., Pörksen, S., Hougaard, P., Beam, C. A., Greenbaum, C. J., BECKER, D. J., Petersen, J. S., Hansen, L. B., et al. (2013) · Pediatric Diabetes · doi:10.1111/pedi.12098 · Cited by 13
Self-citation
B rugia malayisoluble and excretory‐secretory proteins attenuate development of streptozotocin‐induced type 1 diabetes in mice
Amdare, N. P., Khatri, V., Yadav, R. S., Tarnekar, A. M., Goswami, K., & Reddy, M. V. R. (2015) · Parasite Immunology · doi:10.1111/pim.12283 · Cited by 14
Investigating the Role of T-Cell Avidity and Killing Efficacy in Relation to Type 1 Diabetes Prediction
Khadra, A., Pietropaolo, M., Nepom, G. T., & Sherman, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014796 · Cited by 14
Enhanced responsiveness to T‐cell help causes loss of B‐lymphocyte tolerance to a β‐cell neo‐self‐antigen in type 1 diabetes prone NOD mice
Cox, S. L., Stolp, J., Hallahan, N., Counotte, J., Zhang, W., SERREZE, D. V., Basten, A., & Silveira, P. A. (2010) · European Journal of Immunology · doi:10.1002/eji.201040817 · Cited by 14
Immunotherapies in Diabetes Mellitus Type 1
Gupta, S. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.04.008 · Cited by 14
Concise Review: Cell-Based Therapies and Other Non-Traditional Approaches for Type 1 Diabetes
Creusot, R. J., Battaglia, M., Roncarolo, M., & Fathman, C. G. (2016) · Stem Cells · doi:10.1002/stem.2290 · Cited by 14
Activation-induced cytidine deaminase deficiency accelerates autoimmune diabetes in NOD mice
Tan, Q., Tai, N., Li, Y., Pearson, J. A., Pennetti, S., Zhou, Z., Wong, F. S., & Li, W. (2018) · JCI Insight · doi:10.1172/jci.insight.95882 · Cited by 14
A future for CD3 antibodies in immunotherapy of type 1 diabetes
Chatenoud, L. (2019) · Diabetologia · doi:10.1007/s00125-018-4808-7 · Cited by 14
Determining Antigen Specificity of Human Islet Infiltrating T Cells in Type 1 Diabetes
Nakayama, M., & Michels, A. W. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00365 · Cited by 16
Enhanced costimulation by CD70 + B cells aggravates experimental autoimmune encephalomyelitis in autoimmune mice
FrancoSalinas, G., Cantaert, T., Nolte, M. A., Tak, P. P., van Lier, R. A. W., & Baeten, D. (2012) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2012.10.010 · Cited by 14
A SNP in G6PC2 predicts insulin secretion in type 1 diabetes
Sanda, S., Wei, S., Rue, T. C., Shilling, H. G., & Greenbaum, C. J. (2012) · Acta Diabetologica · doi:10.1007/s00592-012-0389-y · Cited by 13
Self-citation
Combination Therapies for Type 1 Diabetes: Why Not Now?
von Herrath, M. (2010) · Immunotherapy · doi:10.2217/imt.10.23 · Cited by 14
Heterogeneity in the presentation of clinical type 1 diabetes defined by the level of risk conferred by human leukocyte antigen class II genotypes
Taka, A., Härkönen, T., Vähäsalo, P., Lempainen, J., Veijola, R., Ilonen, J., Knip, M., & Register, T. F. P. D. (2021) · Pediatric Diabetes · doi:10.1111/pedi.13300 · Cited by 13
Teplizumab: promises and challenges of a recently approved monoclonal antibody for the prevention of type 1 diabetes or preservation of residual beta cell function
Fanaropoulou, N. M., Tsatsani, G. C., Koufakis, T., & Kotsa, K. (2023) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2023.2281990 · Cited by 14
Can fecal microbiota transplantations modulate autoimmune responses in type 1 diabetes?
Snethlage, C. M. F., de Wit, D. F., Wortelboer, K., Rampanelli, E., Hanssen, N. M. J., & Nieuwdorp, M. (2024) · Immunological Reviews · doi:10.1111/imr.13345 · Cited by 13
Revolutionizing type 1 diabetes management: Exploring oral insulin and adjunctive treatments
Nabi‐Afjadi, M., Ostadhadi, S., Liaghat, M., Pasupulla, A. P., Masoumi, S., Aziziyan, F., Zalpoor, H., Abkhooie, L., & Tarhriz, V. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116808 · Cited by 14
The extra-islet pancreas supports autoimmunity in human type 1 diabetes
Barlow, G. L., Schürch, C. M., Bhate, S. S., Phillips, D. J., Young, A., Dong, S., Martinez, H., Kaber, G., Nagy, N., Ramachandran, S., et al. (2025) · eLife · doi:10.7554/elife.100535.3 · Cited by 13
Relationships between major epitopes of the IA-2 autoantigen in Type 1 diabetes: Implications for determinant spreading
McLaughlin, K. A., Richardson, C. C., Williams, S. R., Bonifacio, E. E., Morgan, D., Feltbower, R. G., Powell, M. J., Smith, B. R., Furmaniak, J., & Christie, M. R. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.06.002 · Cited by 13
The latest pharmacotherapy options for type 1 diabetes
Ludvigsson, J. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.855197 · Cited by 13
T–B Lymphocyte Interactions Promote Type 1 Diabetes Independently of SLAM-Associated Protein
Bonami, R. H., Nyhoff, L. E., McNitt, D. H., Hulbert, C., Felton, J. L., Kendall, P. L., & Thomas, J. W. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1900464 · Cited by 13
The Multiple Roles of B Lymphocytes in the Onset and Treatment of Type 1 Diabetes: Interactions between B Lymphocytes and T Cells
Xiao, Y., Deng, C., & Zhou, Z. (2021) · Journal of Diabetes Research · doi:10.1155/2021/6581213 · Cited by 14
The etiology and pathogenesis of type 1 diabetes – A personal, non-systematic review of possible causes, and interventions
Buschard, K. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.876470 · Cited by 15
Subcongenic Analyses Reveal Complex Interactions between Distal Chromosome 4 Genes Controlling Diabetogenic B Cells and CD4 T Cells in Nonobese Diabetic Mice
Stolp, J., Chen, Y., Cox, S. L., Henck, V., Zhang, W., Tsaih, S., Chapman, H. D., Stearns, T. M., SERREZE, D. V., & Silveira, P. A. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200120 · Cited by 13
Regulation of B lymphocyte responses to T oll‐like receptor ligand binding during diabetes prevention in non‐obese diabetic ( NOD ) mice
Wilson, C., Elizer, S. K., Marshall, A. F., Stocks, B. T., & Moore, D. J. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12263 · Cited by 13
Otelixizumab: a novel agent for the prevention of type 1 diabetes mellitus
Miller, S. A., & Onge, E. S. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.610789 · Cited by 13
Magnetically Directed Targeting Aggregation of Radiolabelled Ferrite Nanoparticles
Wang, Y., Fu, C., Chuang, M., Cham, T., & Chung, M. (2011) · Journal of Nanomaterials · doi:10.1155/2011/851520 · Cited by 13
Emerging immune therapies in type 1 diabetes and pancreatic islet transplantation
Schneider, D., Kretowicz, A., & von Herrath, M. G. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12046 · Cited by 14
Immune-Directed Therapy for Type 1 Diabetes at the Clinical Level: The Immune Tolerance Network (ITN) Experience
Ehlers, M. R., & Nepom, G. T. (2012) · The Review of Diabetic Studies · doi:10.1900/rds.2012.9.359 · Cited by 15
Antigen-based vs. systemic immunomodulation in type 1 diabetes
Robert, S., Korf, H., Gysemans, C. A., & Mathieu, C. (2013) · Islets · doi:10.4161/isl.24785 · Cited by 13
Pretransplantation GAD-Autoantibody Status to Guide Prophylactic Antibody Induction Therapy in Simultaneous Pancreas and Kidney Transplantation
Ringers, J., van der Torren, C. R., van de Linde, P., van der Boog, P. J. M., Mallat, M. J. K., Bonifacio, E. E., Roep, B. O., & de Fijter, J. W. (2013) · Transplantation · doi:10.1097/tp.0b013e3182a012cc · Cited by 14
β cell responses to inflammation
Usmani‐Brown, S., Perdigoto, A. L., Lavoie, N., Clark, P. L., Korah, M. M., Rui, J., Betancur, G., & Herold, K. C. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.06.013 · Cited by 14
Disease-modifying pharmacological treatments of type 1 diabetes: Molecular mechanisms, target checkpoints, and possible combinatorial treatments
Kosheleva, L., Koshelev, D., Lagunas‐Rangel, F. A., Levit, S., Rabinovitch, A., & Schiöth, H. B. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100044 · Cited by 12
Artificial intelligence in immunotherapy: revolutionizing diagnostic and therapeutic applications in cancer and autoimmune diseases
Alshorman, J., Mehran, M. J., Bahrami, Y., Mohammadzadeh, S., Barzigar, R., Morshedi, M., Haider, K. H., Tembo, K. M., Rong, S.-J., Jadgal, N., et al. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02107-5 · Cited by 15
Activated polyreactive B cells are clonally expanded in autoantibody positive and patients with recent-onset type 1 diabetes
Nicholas, C. A., Tensun, F., Evans, S. A., Toole, K. P., Prendergast, J. E., BRONCUCIA, H. C., Hesselberth, J. R., Gottlieb, P. A., Wells, K. L., & Smith, M. J. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115425 · Cited by 13
Self-citation
A systematic review and network meta-analysis of interventions to preserve insulin-secreting beta cell function in people newly diagnosed with type 1 diabetes: results from randomised controlled trials of immunomodulatory therapies
Beese, S. E., Price, M. J., Tomlinson, C. L., Sharma, P., Harris, I. M., Adriano, A., Quinn, L. M., Gada, R., Horgan, T. J., Maggs, F., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04201-z · Cited by 18
The role of B cells in regulating the magnitude of immune response
Nagafuchi, S. (2010) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2010.00235.x · Cited by 12
National Institutes of Health Center for Human Immunology Conference, September 2009
Nussenblatt, R. B., Bielekova, B., Childs, R. W., Krensky, A. M., Strober, W., & Trinchieri, G. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05682.x · Cited by 14
Teaching the immune system “self” respect and tolerance
Chatenoud, L. (2014) · Science · doi:10.1126/science.1256864 · Cited by 12
In Situ Evaluation of the Anticancer Antibody Rituximab‐dsDNA Interaction Using a DNA‐Electrochemical Biosensor
Santarino, I. B., Oliveira, S. C. B., & Oliveira‐Brett, A. M. (2014) · Electroanalysis · doi:10.1002/elan.201300488 · Cited by 12
B Cell Metabolism: An Understudied Opportunity to Improve Immune Therapy in Autoimmune Type 1 Diabetes
Wilson, C., & Moore, D. J. (2020) · Immunometabolism · doi:10.20900/immunometab20200016 · Cited by 13

Authors: Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., McGee, P. F., Moran, A. M., Raskin, P., Rodriguez, H., Schatz, D. A., Wherrett, D., Wilson, D. M., Lachin, J. M., & Skyler, J. S.
Affiliations: Indiana University School of Medicine (US)
Benaroya Research Institute (US)
George Washington University (US)
University of Pittsburgh (US)
University of California, San Francisco (US)
Columbia University (US)
University of Colorado Health (US)
University of Miami (US)
University of Minnesota (US)
The University of Texas Southwestern Medical Center (US)
University of Florida (US)
University of Toronto (CA)
Stanford University (US)
ORCID: Greenbaum, Carla J.
Krause-Steinrauf, Heidi
Gitelman, Stephen E.
Gottlieb, Peter A.
Marks, Jennifer B.
Moran, Antoinette M.
Rodriguez, Henry
Schatz, Desmond A.
Wherrett, Diane
Wilson, Darrell M.
Lachin, John M.
Skyler, Jay S.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2009-11-26
Volume: 361
Issue: 22
Pages: 2143-2152
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa0904452
PMC: PMC6410357
OpenAlex: W2064431167
Cited by: 1,093
References: 39
Citations by year: 2026: 45 · 2025: 65 · 2024: 56 · 2023: 55 · 2022: 56 · 2021: 64 · 2020: 53 · 2019: 49 · 2018: 49 · 2017: 45 · 2016: 57 · 2015: 63 · 2014: 72 · 2013: 98 · 2012: 89
FWCI: 51.38
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
IUScholarWorks (Indiana University) (submittedVersion)
Purdue University Indianapolis (Indiana University) (submittedVersion)
PMC
Funders: American Diabetes Association
Juvenile Diabetes Research Foundation International
Eli Lilly and Company
Biogen
Osiris Therapeutics
MacroGenics
National Institutes of Health
Genentech
National Institute of Allergy and Infectious Diseases
National Institute of Diabetes and Digestive and Kidney Diseases (R21DK077329, U01DK061058, U01DK061034, U01DK103282)
National Institute of Child Health and Human Development
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords: rituximab, B-cell depletion, type 1 diabetes, beta-cell preservation, anti-CD20 monoclonal antibody, C-peptide, CD19+ B cells, immunopathogenesis, newly diagnosed type 1 diabetes, HbA1c, insulin dose
MeSH terms: Rituximab, Adolescent, Adult, Antibodies, Monoclonal, B-Lymphocytes, C-Peptide, Child, Diabetes Mellitus, Type 1, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Immunoglobulin M, Immunologic Factors, Male, Area Under Curve, Insulin-Secreting Cells, Young Adult, Antibodies, Monoclonal, Murine-Derived

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks